Based on this YouTube video's total view count of 167K views and industry-standard rates, the estimated total earning is $117 - $335 through ad revenue. Historical data is not yet available to calculate daily, weekly, or monthly averages.

Explore Coronavirus, Most promising treatment so far with 167,631 views, 5,928 likes, and 1,281 comments. Experience the impact of this video content that has captured audience attention.

Well, probably. Synairgen's SNG001, Interferon beta £21.29 per injection http://www.pharmatimes.com/news/synairgens_sng001_shows_strong_promise_in_covid-19_trial_1345119 Interferon beta Naturally occurring antiviral protein Cytokine Interfere with viral replication Induce fever and muscle pains (along with other cytokines) Activate immune cells, natural killer cells and macrophages Reduces protein synthesis in adjacent cells Activates an enzyme to destroy RNA, further reducing protein synthesis Stimulates many other interferon-stimulated genes Stimulates infected cells into apoptosis Key component of human immune defence against viral infection https://www.sciencemediacentre.org/expert-reaction-to-announcement-by-synairgen-that-their-drug-sng001-has-had-positive-results-in-initial-trials-on-covid-19-patients/ Phase 2 study Inhaled interferon beta Gives high local concentrations Placebo controlled n = 101 hospitalised patients All patients tested positive for SARS-CoV-2 9 UK hospitals Diabetics Treatment group = 9 Placebo group = 3 Cardiovascular disease Treatment group = 5 Placebo group = 8 Now recruiting patients ill with COVID-19 in the community Results 79% reduction in risk of developing severe disease Requiring ventilation or resulting in death During the treatment period Day one to day 16 This difference was also noted to day 28 Patients who received SNG001 were more than twice as likely to recover Defined as ‘no limitation of activities’ or ‘no clinical or virological evidence of infection’ Measure of breathlessness, markedly reduced In patients with more severe disease at time of admission SNG001 increased the likelihood of hospital discharge during the study Six days versus nine days for those receiving placebo (not significant difference) More than twice as likely to have recovered by the end of the treatment period (strong trend) Safety 6% died after being randomised to placebo No deaths in the SNG001 group Professor Tom Wilkinson Professor of Respiratory Medicine, University of Southampton Trial chief investigator Huge potential To be able to restore the lung’s immune response Enhancing protection Accelerating recovery Countering the impact of SARS-CoV-2 virus Professor Stephen Holgate Medical Research Council Clinical Professor of Immunopharmacology at the University of Southampton Restores the lung’s ability to neutralise the virus or any mutation of the virus or co-infection with another respiratory virus such as influenza Relationship with dexamethasone and remdesivir Study did not include patients requiring ventilatory support

With SocialCounts.org’s view counter, track your YouTube video’s live view count and YouTube likes count in real time with fast, reliable updates.

Watch every YouTube video live view count rise with our real-time YouTube views tracker—built for accuracy and minimal delay.

Follow YouTube real time views as they happen, using our dedicated view counter for YouTube videos.

Get up-to-date live view count on YouTube and see real-time growth with SocialCounts.org’s smart tracking tools.